Agilent Technologies Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Agilent Technologies Inc trades at $148.51 (market cap $42.22B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.27. The key difference: Agilent Technologies Inc pays a 0.68% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| A | VCIT | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Fixed Income |
52-Week High | $157.20 | $84.82 |
52-Week Low | $110.24 | $81.07 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.295 with a modest 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The fund maintains competitive advantages with its ultra-low 0.03% expense ratio and approximately 5% yield, holding over 2,000 investment-grade corporate bonds. Recent dividend distributions of $0.33-0.34 highlight its income-focused strategy.
The outlook for VCIT remains favorable for income investors seeking corporate bond exposure with low costs. Key opportunities include the fund's yield advantage over treasury alternatives and consistent monthly distributions. Risks involve interest rate sensitivity and corporate credit quality concerns during economic uncertainty. Wall Street sentiment is generally positive given the fund's cost efficiency and diversification benefits.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →